Search results for "agonists"

showing 10 items of 1616 documents

The Endogenous Opioid System Is Not Involved in Modulation of Opioid-Induced Hyperalgesia

2009

Abstract Some recent studies suggested a role of the endogenous opioid system in modulating opioid-induced hyperalgesia (OIH). In order to test this hypothesis, we conducted a prospective randomized, placebo-controlled, 2-way crossover study in healthy human volunteers. We utilized a well-established model of inducing OIH after a brief exposure to the μ-opioid agonist remifentanil using intradermal electrical stimulation. Patients were exposed to a randomized 90-minute infusion of remifentanil or saline placebo during 2 separate occasions. Development of OIH was quantified using changes in the average radius of the area of secondary hyperalgesia generated by electrical pain stimulation. A 2…

AdultMaleAgonistmedicine.drug_classNarcotic AntagonistsRemifentanilBlood PressureStimulationPharmacologyPlaceboRemifentanilYoung AdultDouble-Blind MethodPiperidinesHeart RatemedicineHumansOpioid-induced hyperalgesiaPain MeasurementEndogenous opioidCross-Over StudiesNaloxonebusiness.industryMiddle AgedAnalgesics OpioidAnesthesiology and Pain MedicineNeurologyOpioidHyperalgesiaAnesthesiaHyperalgesiaNeurology (clinical)medicine.symptombusinessmedicine.drugThe Journal of Pain
researchProduct

Reduced penetrance of autosomal dominant hypercholesterolemia in a high percentage of families: importance of genetic testing in the entire family.

2011

Abstract Background Autosomal dominant hypercholesterolemias (ADHs) are characterised by increased plasma levels of total and LDL cholesterol, predisposing to premature atherosclerosis. ADHs comprise several diseases with undistinguishable phenotype, caused by mutations in different genes: LDLR, APOB and PCSK9. Genetic studies are usually performed in patients with altered cholesterol levels. However, some persons carrying pathogenic mutations are normocholesterolemic and there are no further studies about this subject. We have studied the frequency of families and individuals carrying ADH mutations who do not present the disease in Spanish population. Methods We have analysed genes known t…

AdultMaleApolipoprotein BAdolescentFamilial hypercholesterolemiaBiologymedicine.disease_causeHyperlipoproteinemia Type IIChlorocebus aethiopsmedicineAnimalsHumansGenetic TestingChildGeneGenetic testingAgedApolipoproteins BGeneticsFamily HealthMutationmedicine.diagnostic_testurogenital systemPCSK9Serine EndopeptidasesCholesterol LDLSequence Analysis DNAMiddle Agedmedicine.diseasePenetrancePhenotypePedigreePhenotypeMutagenesisSpainApolipoprotein B-100COS CellsMutationbiology.proteinFemaleProprotein ConvertasesProprotein Convertase 9Cardiology and Cardiovascular Medicinehormones hormone substitutes and hormone antagonistsAtherosclerosis
researchProduct

Procalcitonin levels in candidemia versus bacteremia: a systematic review

2019

Background Procalcitonin (PCT) is a biomarker used to assess systemic inflammation, infection, and sepsis and to optimize antimicrobial therapies. Its role in the in the differential diagnosis between candidemia and bacteremia is unclear. The aim of this systematic review was to summarize the current evidence about PCT values for differentiating candidemia from bacteremia. Methods PubMed and EMBASE were searched for studies reporting data on the diagnostic performance of serum PCT levels in intensive care unit (ICU) or non-ICU adult patients with candidemia, in comparison to patients with bacteremia. Results We included 16 studies for a total of 45.079 patients and 785 cases of candidemia. …

AdultMaleCalcitoninmedicine.medical_specialtyLetterBacteremiaCritical Care and Intensive Care MedicineProcalcitoninlaw.inventionSepsis03 medical and health sciences0302 clinical medicineBiomarker; Candida; Candidemia; Fungal; Fungi; PCT; Procalcitonin; SepsislawSecondary analysisSepsisparasitic diseasesmedicineHumansIntensive care medicineCandidaAdult patientsbusiness.industryResearchlcsh:Medical emergencies. Critical care. Intensive care. First aidFungiCandidemia030208 emergency & critical care medicinelcsh:RC86-88.9Biomarkermedicine.diseasebacterial infections and mycosesIntensive care unitFungalBacteremiaBiomarker (medicine)FemaleDifferential diagnosisbusinessPCTProcalcitoninhormones hormone substitutes and hormone antagonistsBiomarkersCritical Care
researchProduct

The use of esmolol in whole-body hyperthermia: Cardiovascular effects

1997

Whole-body hyperthermia (WBH) is a well-described investigational adjunct to systemic chemotherapy for the treatment of advanced malignancies. The hemodynamic consequences of this physiologic state may include tachycardia, which can produce acute myocardial ischemia in patients with coronary artery disease. Ischemic heart disease is currently considered a contraindication to WBH. We chose to investigate the consequences of using a new beta 1-adrenergic antagonist, esmolol, to attempt to control the tachycardia associated with WBH. After institutional approval and patient consent, nine consecutive patients with normal cardiac function presenting for WBH with carboplatin infusion were studied…

AdultMaleCancer ResearchMean arterial pressureCardiac outputHeart diseasePhysiologySinus tachycardiaAdrenergic beta-AntagonistsCardiac indexAntineoplastic AgentsCoronary DiseaseCarboplatinPropanolaminesHeart RateNeoplasmsTachycardiaPhysiology (medical)Heart rateHumansMedicineInfusions Intravenousbusiness.industryContraindicationsHemodynamicsHyperthermia InducedMiddle Agedmedicine.diseaseEsmololCombined Modality TherapyAnesthesiaHeart failureFemaleSafetymedicine.symptombusinessmedicine.drugInternational Journal of Hyperthermia
researchProduct

Reference interval determination for N-terminal-B-type natriuretic peptide (NT-proBNP): A study in blood donors

2005

We assessed reference values in a group of apparently healthy blood donors. A total of 1980 blood donors was recruited and tested for the presence of NT-proBNP using a newly developed electrochemiluminescence immunoassay (ECLIA) method. NT-proBNP clustered in all blood donors below the age of 50 years and an upper limit of normal (ULN) was found to be 84 pg/ml for males and 146 pg/ml for females. Mean NT-proBNP values increased with increasing age which was due to an increasing number of individuals exceeding the ULN. Age- and gender-appropriate NT-proBNP levels decreased with increasing hemoglobin levels. Hemoglobin but not creatinine levels influenced the NT-proBNP concentration in this c…

AdultMaleCardiac function curvemedicine.medical_specialtyLuminescenceAdolescentmedicine.drug_classClinical BiochemistryRenal functionBlood DonorsHemoglobin levelsBiochemistryHemoglobinschemistry.chemical_compoundSex FactorsReference ValuesInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideHumanscardiovascular diseasesAgedImmunoassayCreatinineBiochemistry (medical)Age FactorsGeneral MedicineMiddle AgedPeptide FragmentsEndocrinologychemistryCreatinineReference valuesCohortFemaleHemoglobinhormones hormone substitutes and hormone antagonistsClinica Chimica Acta
researchProduct

Effects of Intravenous Corticotropin-Releasing Hormone upon Sleep-Related Growth Hormone Surge and Sleep EEG in Man

1988

Corticotropin-releasing hormone (CRH) plays a key role in coordinating neuroendocrine, metabolic and behavioral responses in stress and affective disorders. To further investigate the effects of enhanced pituitary-adrenocortical activity upon sleep-related phenomena we administered four intravenous injections of 50 micrograms human (h)-CRH or saline to 11 normal males at 10 p.m., 11 p.m., 12 p.m. and 1 a.m. and measured plasma levels of cortisol and growth hormone (GH) as well as sleep EEG recordings throughout the night. Treatment with h-CRH resulted in a significant increase of mean (+/- SEM) cortisol secretion between 11 p.m. and 3 a.m. (h-CRH: 100.6 +/- 9.5 ng/ml; saline: 39.0 +/- 1.5 n…

AdultMaleCortisol secretionendocrine systemmedicine.medical_specialtyCorticotropin-Releasing HormoneEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPituitary-Adrenal SystemPeptide hormoneCellular and Molecular NeuroscienceCorticotropin-releasing hormoneEndocrinologyInternal medicinemedicineHumansSalineSlow-wave sleepEndocrine and Autonomic SystemsChemistryElectroencephalographySleep in non-human animalsEndocrinologyGrowth HormoneInjections IntravenousSleepSleep eeghormones hormone substitutes and hormone antagonistsHormoneNeuroendocrinology
researchProduct

Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine : a phase 2 randomised, placebo-control…

2012

Lasmiditan (COL-144) is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study. We aimed to assess the efficacy and safety of oral lasmiditan for the acute treatment of migraine.In this multicentre, double-blind, parallel-group, dose-ranging study in 43 headache centres in five European countries, patients with migraine with and without aura and who were not using prophylaxis were randomly assigned (1:1:1:1:1) to treat one moderate or severe attack at home with 50 mg, 100 mg, 200 mg, or 400 mg lasmiditan, or placebo. Study drug and placebo were sup…

AdultMaleDrug-Related Side Effects and Adverse ReactionsPyridinesPopulationMedizinAdministration OralKaplan-Meier EstimatePlacebolaw.inventionYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodPiperidinesRandomized controlled triallawHumansMedicineAdverse effecteducationAgededucation.field_of_studyDose-Response Relationship Drugbusiness.industryMiddle AgedDose-ranging studymedicine.diseaseLasmiditanSerotonin Receptor Agonists3. Good healthTreatment OutcomechemistryTolerabilityMigraine030220 oncology & carcinogenesisAnesthesiaBenzamidesFemaleNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Reduced oxytocin receptor gene expression and binding sites in different brain regions in schizophrenia: A post-mortem study

2016

Schizophrenia is a severe neuropsychiatric disorder with impairments in social cognition. Several brain regions have been implicated in social cognition, including the nucleus caudatus, prefrontal and temporal cortex, and cerebellum. Oxytocin is a critical modulator of social cognition and the formation and maintenance of social relationships and was shown to improve symptoms and social cognition in schizophrenia patients. However, it is unknown whether the oxytocin receptor is altered in the brain. Therefore, we used qRT-PCR and Ornithine Vasotocin Analog ([125I]OVTA)-based receptor autoradiography to investigate oxytocin receptor expression at both the mRNA and protein level in the left p…

AdultMaleGene ExpressionVasotocinReal-Time Polymerase Chain ReactionLeft nucleusRats Sprague-Dawley03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineHaloperidolAnimalsHumansRNA MessengerClozapineBiological PsychiatryClozapineAgedAged 80 and overTemporal cortexBinding SitesBrainMiddle Agedmedicine.diseaseOxytocin receptor030227 psychiatryPsychiatry and Mental healthchemistryOxytocinReceptors OxytocinSchizophreniaSchizophreniaAutoradiographyHaloperidolFemalePsychologyNeurosciencehormones hormone substitutes and hormone antagonists030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drugSchizophrenia Research
researchProduct

Effect of serotonin uptake inhibition by zimelidine on hypothalamic-pituitary-adrenal activity

1983

Plasma ACTH levels after oral ingestion of 2 g metyrapone at 24.00 hours in six healthy subjects were higher after pretreatment with zimelidine (300 mg) in comparison to placebo. Since zimelidine is a relatively selective serotonin reuptake inhibitor its action on hypothalamic-pituitary-adrenal (HPA) activity suggests that serotonin is a potent stimulator of ACTH release. The ratio of cortisol to 11-deoxycortisol was taken as a measure of 11-hydroxylase activity, which indicates biological activity of secreted ACTH. These cortisol/11-deoxycortisol ratios were significantly increased after zimelidine treatment, when compared to placebo. Both the ACTH response and the cortisol/11-deoxycortiso…

AdultMaleHypothalamo-Hypophyseal SystemSerotoninendocrine systemmedicine.medical_specialtySerotonin uptakePyridinesSerotonin reuptake inhibitorPituitary-Adrenal SystemPharmacologyPlaceboPlacebosAdrenocorticotropic HormoneInternal medicinemedicineHumansZimelidinePharmacologyMetyraponeChemistryPhysiological conditionZimeldineBiological TransportBiological activityBrompheniramineEndocrinologySerotonin AntagonistsSerotoninhormones hormone substitutes and hormone antagonistsmedicine.drugPsychopharmacology
researchProduct

Hypothalamic-pituitary-thyroid axis in acromegaly

1983

To evaluate the hypothalamic-pituitary-thyroid axis in acromegaly, total and free thyroid hormones and TSH response to TRH were determined in 36 acromegalic patients. In 10 patients, rT3 and thyroxine binding globulin (TBG) were also assayed by radioimmunoassay. In 15 patients the TSH response to TRH was also studied after medical or surgical therapy of the acromegaly. In 34 patients total thyroid hormones were in the normal range whereas two patients had low serum levels of free thyroid hormones. Thirty-two of the acromegalic patients were euthyroid. However, only 43.7% of the euthyroid patients had a normal TSH response to TRH. Nine patients had a reduced TSH rise after TRH, whereas in 4 …

AdultMaleHypothalamo-Hypophyseal Systemendocrine systemmedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and MetabolismThyroid GlandThyrotropinThyroid Function TestsThyroxine-binding globulinEndocrinologyTRH stimulation testInternal medicineAcromegalymedicineHumansEuthyroidThyrotropin-Releasing Hormonebiologybusiness.industryThyroidMiddle Agedmedicine.diseaseHypothalamic–pituitary–thyroid axisThyroxinemedicine.anatomical_structureEndocrinologyHypothalamusAcromegalybiology.proteinTriiodothyronineFemaleThyroid functionbusinesshormones hormone substitutes and hormone antagonistsJournal of Endocrinological Investigation
researchProduct